DaVita HealthCare Partners Inc (DVA)vsSyra Health Corp. Class A Common Stock (SYRA)
DVA
DaVita HealthCare Partners Inc
$155.11
+1.19%
HEALTHCARE · Cap: $10.25B
SYRA
Syra Health Corp. Class A Common Stock
$0.18
0.00%
HEALTHCARE · Cap: $2.11M
Smart Verdict
WallStSmart Research — data-driven comparison
DaVita HealthCare Partners Inc generates 188705% more annual revenue ($13.64B vs $7.23M). DVA leads profitability with a 5.5% profit margin vs -12.4%. DVA earns a higher WallStSmart Score of 66/100 (B-).
DVA
Strong Buy66
out of 100
Grade: B-
SYRA
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.7%
Fair Value
$163.40
Current Price
$155.11
$8.29 discount
Intrinsic value data unavailable for SYRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 65 in profit
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
5.5% margin — thin
Weak financial health signals
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -36.0% — below average capital efficiency
Revenue declined 13.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : DVA
The strongest argument for DVA centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : SYRA
The strongest argument for SYRA centers on Price/Book, Debt/Equity.
Bear Case : DVA
The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.
Bear Case : SYRA
The primary concerns for SYRA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DVA profiles as a value stock while SYRA is a turnaround play — different risk/reward profiles.
SYRA carries more volatility with a beta of 3.96 — expect wider price swings.
DVA is growing revenue faster at 9.9% — sustainability is the question.
DVA generates stronger free cash flow (395M), providing more financial flexibility.
Bottom Line
DVA scores higher overall (66/100 vs 28/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DaVita HealthCare Partners Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Syra Health Corp. Class A Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Syra Health Corp. The company is headquartered in Carmel, Indiana.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?